MAIA Biotechnology, Inc.

Overview

Compare with another stock.

• TickerMAIA on NYSE¹
• IndustryPharmaceutical Preparations¹
• HeadquartersChicago, Illinois¹
• Incorporated inDE²
• Business address444 West Lake Street, Suite 1700, Chicago, Il 60606²
• Filer category, Emerging growth company²
• Legal formCorporation

See how the biggest companies compare on our leaderboards

The patients received either 60mg, 180mg, or 360mg of ateganosine per dose, and 42 had at least one post baseline assessment completed.³ From its latest annual report

Corporate structure

MAIA Biotechnology, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What MAIA Biotechnology, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

Properties, in its own words

Our headquarters is in Chicago, Illinois where we currently lease office space with approximately 124 square feet under a twelve month lease starting in April 2025, under which we currently pay $3,325 per month. We believe that this space is sufficient to meet our needs for the foreseeable future and that any additional space we may require will be available on commercially reasonable terms. Additionally, we intend to maintain our business model designed to leverage virtual technology to minimize brick and mortar facilities while optimizing our ability to attract top talented employees that may reside in any geography.

Item 2 of the 10-K filed Mar 23, 2026.³

Leadership

Who has led MAIA Biotechnology, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerVlad Vitoc Jul 27, 2022 to now¹⁰
• Chief financial officerJoseph F. McGuire Jul 27, 2022 to Jun 5, 2023¹¹

Named in SEC Form D filings

People the company listed in its private-offering notices.

• DirectorLouie Ngar Yee named Nov 12, 2024 to Jan 5, 2026²²

Timeline

1. Oct 6, 20268-K Regulation FD disclosure²³
2. May 22, 20268-K Shareholder vote²⁴
3. May 14, 20268-K Ended a material agreement²⁵
4. Apr 16, 20268-K Other events²⁶
5. Apr 8, 20268-K Other events²⁷
6. Apr 2, 20268-K Executive or director change²⁸
7. Mar 31, 20268-K Other events²⁹
8. Mar 27, 20268-K Regulation FD disclosure; Other events³⁰
9. Mar 4, 20268-K Entered a material agreement; Other events³¹
10. Feb 24, 20268-K Other events³²
11. Jan 20, 20268-K Other events³³
12. Jan 13, 20268-K Regulation FD disclosure; Other events³⁴
13. Jul 27, 2022New chief executive Vlad Vitoc becomes CEO¹⁰

Calendar

Coming up

1. Nov 6, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.27) a share, on Nov 7, 2025.³⁵

When it reported results

1. Nov 7, 2023Reported quarterly or annual results³⁶
2. Aug 8, 2023Reported quarterly or annual results³⁷
3. May 8, 2023Reported quarterly or annual results³⁸
4. Mar 24, 2023Reported quarterly or annual results³⁹
5. Nov 9, 2022Reported quarterly or annual results⁴⁰
6. Aug 22, 2022Reported quarterly or annual results⁴¹

Drug trials and FDA: coming up

1. Jul 31, 2027Phase 3 trial readout expected Phase 3 trial of 6-Thio-2'-Deoxyguanosine, Cemiplimab and others in Carcinoma, Non-Small -Cell Lung: primary completion expected Jul 31, 2027 (ClinicalTrials.gov NCT06908304).⁴²
2. Sep 30, 2027Phase 2 trial readout expected Phase 2 trial of 6-Thio-2'-Deoxyguanosine and Cemiplimab in Carcinoma, Non-Small-Cell Lung: primary completion expected Sep 30, 2027 (ClinicalTrials.gov NCT05208944).⁴³

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

503 filings to the SEC since October 2021: 4 annual reports, 14 quarterly reports, 110 major events, 248 insider forms, 12 large holders, 7 private raises, 108 other. The latest 20:

1. Oct 7, 2026424B3 EDGAR
2. Oct 6, 2026EFFECT EDGAR
3. Oct 6, 20268-K EDGAR
4. Oct 2, 20264 PRIMARY DOCUMENT EDGAR
5. Oct 2, 20264 PRIMARY DOCUMENT EDGAR
6. Oct 2, 20264 PRIMARY DOCUMENT EDGAR
7. Oct 2, 20264 PRIMARY DOCUMENT EDGAR
8. Oct 2, 20264 PRIMARY DOCUMENT EDGAR
9. Oct 2, 20264 PRIMARY DOCUMENT EDGAR
10. Oct 2, 2026424B3 EDGAR
11. Sep 25, 2026S-3 EDGAR
12. Sep 15, 20264 PRIMARY DOCUMENT EDGAR
13. Sep 14, 20264 PRIMARY DOCUMENT EDGAR
14. Sep 1, 20264 PRIMARY DOCUMENT EDGAR
15. Aug 28, 2026EFFECT EDGAR
16. Aug 26, 20264 PRIMARY DOCUMENT EDGAR
17. Aug 24, 20264 PRIMARY DOCUMENT EDGAR
18. Aug 21, 2026S-3 EDGAR
19. Aug 14, 2026SCHEDULE 13G/A EDGAR
20. Aug 10, 202610-Q EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

145 open-market trades by officers, directors and large owners since October 2021: 145 buys and 0 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Solas Capital Management, LLCSCHEDULE 13G/A, 2 filings May 15, 2026 to Aug 14, 2026⁴⁴
• Vlad VitocSCHEDULE 13D/A, 3 filings Feb 14, 2023 to Dec 4, 2025⁴⁵
• FGMK Business Holdings, LLCSCHEDULE 13G, 1 filing Mar 3, 2025⁴⁶
• Sergei GryaznovSCHEDULE 13G/A, 2 filings Feb 14, 2023 to Feb 14, 2025⁴⁷
• Ngar Yee LouieSC 13D, 2 filings Feb 14, 2023 to Oct 25, 2024⁴⁸
• Stan SmithSC 13D/A, 2 filings Aug 10, 2022 to Oct 25, 2024⁴⁹

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Dec 22, 2025Raised $1.5 million in a private offering of equity²² Form D: $2 million offered in all Form D
2. Sep 29, 2025Raised $3 million in a private offering of equity⁵¹ Form D: $7 million offered in all Form D
3. May 28, 2025Raised $694,998 in a private offering of equity⁵² Form D: $8 million offered in all Form D
4. Feb 18, 2025Raised $4.1 million in a private offering of equity⁵³ Form D: $5.9 million offered in all Form D
5. Oct 28, 2024Raised $2.4 million in a private offering of equity⁵⁴ Form D: $15.5 million offered in all Form D
6. Mar 11, 2024Raised $2.9 million in a private offering of equity⁵⁵ Form D: $5.7 million offered in all Form D
7. Nov 15, 2023Raised $4.9 million in a private offering of equity⁵⁶ Form D: 3 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 36. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How MAIA Biotechnology, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARMAIA Biotechnology, Inc.¹
• CIK0001878313
• Employer ID (EIN)83-1495913³
• Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company³
• Incorporated inDelaware³
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address444 West Lake Street, Suite 1700, Chicago, IL 60606¹
• Phone312-416-8592¹
• Shares outstanding60,825,844 as of Aug 10, 2026⁹
• Public float$48.9M as of Jun 30, 2025³
• AuditorGRANT THORNTON LLP, Charlotte, North Carolina PCAOB ID 248; no auditor attestation of internal control over financial reporting³
• On EDGAR sinceOct 15, 2021¹
• Filings503 in all: 4 (231), 8-K (109), CORRESP (25), 10-Q (13), 3 (12), 424B5 (11), UPLOAD (11), S-1/A (9)¹
  All 38 form types

  FWP (8), D (7), 4/A (5), EFFECT (5), S-8 (5), 10-K (4), DEF 14A (4), DEFA14A (4), 424B3 (3), DRS (3), S-1 (3), S-3 (3), SC 13D (3), SC 13G (3), 424B4 (2), DRS/A (2), DRSLTR (2), SCHEDULE 13G (2), SCHEDULE 13G/A (2), SEC STAFF LETTER (2), 10-Q/A (1), 144 (1), 8-A12B (1), 8-K/A (1), ARS (1), CERT (1), PRE 14A (1), RW (1), SC 13D/A (1), SCHEDULE 13D/A (1)

• Latest filingsAnnual report (10-K) Mar 23, 2026
  Quarterly report (10-Q) Aug 10, 2026
  Proxy statement (DEF 14A) Apr 7, 2026
  Latest 8-K (8-K) Oct 6, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 23, 2026 (Section 12(b) of the Exchange Act).³

Risk factors and legal proceedings

The risks MAIA Biotechnology, Inc. names in Item 1A of its 10-K filed Mar 23, 2026: 71 risks under these headings, as written.³

• Risks Related to Our Financial Position and Need for Additional Capital
• We have incurred losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability.
• We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of ateganosine.
• Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
• We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability.
• Risks Related to Development, Clinical Trials, Manufacturing and Regulatory Approval
• We are heavily dependent on the success of ateganosine, our most advanced candidate, which is still under clinical development, and if this drug does not receive regulatory approval or is not successfully commercialized, our business may be harmed.
• Pandemics, such as COVID-19, may adversely impact our business, results of operations, financial condition, liquidity and cash flows and that of our clients.
• Clinical trials are expensive, time-consuming and difficult to design and implement, and involve an uncertain outcome.
• Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval.
• Serious adverse events, undesirable side effects or other unexpected properties of our product candidates may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval, revocation of marketing authorizations or limitations on the use of our product candidates thereby limiting the commercial potential of such product candidate.
• Interim, topline and preliminary data from our clinical trials may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.

Legal proceedings

At the date of the Annual Report on Form 10-K, we are not party to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.

The opening of Item 3, Legal Proceedings.³